NCT00466895 - Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

July 31, 2016

Conditions

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia

Interventions

DRUG

lenalidomide

Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus